Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores.

IF 1.5 4区医学 Q4 IMMUNOLOGY AIDS research and human retroviruses Pub Date : 2024-10-29 DOI:10.1089/aid.2024.0066

Arturo Ciccullo, Valentina Iannone, Damiano Farinacci, Rebecca Jo Steiner, Francesca Lombardi, Andrea Carbone, Pierluigi Francesco Salvo, Gianmaria Baldin, Alberto Borghetti, Simona Di Giambenedetto

{"title":"Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores.","authors":"Arturo Ciccullo, Valentina Iannone, Damiano Farinacci, Rebecca Jo Steiner, Francesca Lombardi, Andrea Carbone, Pierluigi Francesco Salvo, Gianmaria Baldin, Alberto Borghetti, Simona Di Giambenedetto","doi":"10.1089/aid.2024.0066","DOIUrl":null,"url":null,"abstract":"The Aim of this study is to assess the cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF). We analyzed data from 37 virologically suppressed people living with HIV starting DOR/3TC/TDF, collecting viro-immunological and metabolic parameters as well as the 10-year risk of cardiovascular disease (10Y-CD) using both the Framingham risk score and D:A:D score.After 48 weeks, we observed a significant reduction in 10Y-CD both via the Framingham score (-0.7, p = .021) and the D:A:D score (-0.41, p = .012). After 96 weeks, we registered a significant reduction in 10Y-CD calculated via the D:A:D score (-0.98, p = .009). Regarding serum lipid markers, after 48 weeks we observed a significant reduction in total cholesterol (-17 mg/dL, p < .001), triglycerides (-21 mg/dL, p = .015), and LDL cholesterol (-8 mg/dL, p = .022). After 96 weeks, we registered a significant reduction in total cholesterol (-19 mg/dL, p < .001). DOR/3TC/TDF has shown a favorable metabolic profile, with a significant reduction in 10Y-CD, independently from the use of lipid-lowering drugs.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/aid.2024.0066","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Aim of this study is to assess the cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF). We analyzed data from 37 virologically suppressed people living with HIV starting DOR/3TC/TDF, collecting viro-immunological and metabolic parameters as well as the 10-year risk of cardiovascular disease (10Y-CD) using both the Framingham risk score and D:A:D score.After 48 weeks, we observed a significant reduction in 10Y-CD both via the Framingham score (-0.7, p = .021) and the D:A:D score (-0.41, p = .012). After 96 weeks, we registered a significant reduction in 10Y-CD calculated via the D:A:D score (-0.98, p = .009). Regarding serum lipid markers, after 48 weeks we observed a significant reduction in total cholesterol (-17 mg/dL, p < .001), triglycerides (-21 mg/dL, p = .015), and LDL cholesterol (-8 mg/dL, p = .022). After 96 weeks, we registered a significant reduction in total cholesterol (-19 mg/dL, p < .001). DOR/3TC/TDF has shown a favorable metabolic profile, with a significant reduction in 10Y-CD, independently from the use of lipid-lowering drugs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯对病毒已被抑制的 PLWHIV 的心血管安全性：心血管疾病评分比较分析》。

本研究旨在评估多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯（DOR/3TC/TDF）的心血管安全性。我们分析了 37 名开始服用 DOR/3TC/TDF 的病毒学抑制的 HIV 感染者的数据，收集了病毒免疫和代谢参数，并使用弗雷明汉风险评分和 D:A:D 评分评估了 10 年心血管疾病风险（10Y-CD）。96 周后，通过 D:A:D 评分计算得出的 10Y-CD 显著下降（-0.98，p = .009）。在血清脂质指标方面，48 周后，我们观察到总胆固醇（-17 毫克/分升，p < .001）、甘油三酯（-21 毫克/分升，p = .015）和低密度脂蛋白胆固醇（-8 毫克/分升，p = .022）显著下降。96 周后，总胆固醇显著降低（-19 mg/dL，p < .001）。DOR/3TC/TDF显示出良好的代谢状况，10Y-CD显著降低，与降脂药物的使用无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

AIDS research and human retroviruses 医学-病毒学

CiteScore

3.10

自引率

6.70%

发文量

201

审稿时长

3-6 weeks

期刊介绍： AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.